To ascertain the role of antigen recognition by cancer cells in BLM’s antitumor effects, we conducted knockdown (KD) experiments targeting B2m, a pivotal component of MHC-I molecules, in B16OVA cells (Supplemental Figure 8A). Here, B2M is linked to cancer.